Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
El-Shakankery KH, Kefas J, Palmer K, Houston A, Mukherjee U, Gao K, Tan W, Crusz SM, Flynn MJ, Ledermann JA, Lockley M, McCormack M, MacDonald N, Nicum S, Devlin MJ and Miller RE
Cancers, Mdpi vol. 16 (21) 
24-10-2024

A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population
Merry E, Kesmez RT, Yu T, Flynn M, Ledermann J, Lockley M, Macdonald N, McCormack M, Nicum S, Crusz S and Miller R
International Journal of Gynecological Cancer, Bmj 
03-09-2024

Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer
Oxley S, Ahmed S, Baxter K, Blake D, Braden V, Brincat MR, Bryan S, Dilley J, Dobbs S, Durden A, Gomes N, Johnston B, Kaushik S, Kokka F, Lockley M, Lowe-Zinola J, Manchanda R, McCormick A, Nott C, Owens GL, Pandya A, Prince J, Ryan N, Sideris M, Tanna S, Waters J, Zamesa N, Thomas M and Olaitan A
International Journal of Gynecological Cancer, Elsevier vol. 34 (11), 1768-1774.  
24-08-2024

Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004–2016) analysis
Sullivan SM, Stoneham S, Lockley M, Frazier AL, Billmire DF and Poynter JN
International Journal of Gynecological Cancer, Bmj vol. 34 (12) 
01-07-2024

Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer
Manchanda R, Sun L, Wei X and legood R
Journal of The National Comprehensive Cancer Network : Jnccn, Jones and Barlett Publishers 
18-04-2024

Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T, Hirsch MS, Lockley M, Stoneham S and Frazier AL
Eclinicalmedicine, Elsevier vol. 69 
06-02-2024

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention
Nuttall Musson E, Miller RE, Mansour MR, Lockley M, Ledermann JA and Payne EM
Leukemia, Springer Nature vol. 38 (1), 215-218.  
17-11-2023

Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and Myelodysplastic Syndrome: A Case Series
Musson EN, Lockley M, Mansour MR, Miller RE, Lederman J and Payne E
Blood, American Society of Hematology vol. 142 (Supplement 1) 
02-11-2023

Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy
Wood GE, Bunting CP, Veli M, Arora R, Berney DM, Alifrangis C, MacDonald ND, Miller RE, Shamash J, Stoneham S and Lockley M
Frontiers in Oncology, Frontiers vol. 13 
25-10-2023

Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M and Frazier AL
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 42 (6), 696-706.  
11-10-2023

Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE, Mills‐Baldock T, Crusz SM, Sun L, Evans O, Robbani S, Jenkins LA, Ahmed M, Kumar A, Quigley M, Lockley M, Faruqi A, Casey L, Brockbank E, Phadnis S, Trevisan G, Singh N, Legood R and Manchanda R
Bjog An International Journal of Obstetrics & Gynaecology, Wiley vol. 131 (6), 848-857.  
26-09-2023

Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana I-G, Reinius MAV, Giannone G, Lewsley L-A, Stobo J, McQueen J, Bryson G, Eldridge M, Macintyre G, Markowetz F, Brenton JD and McNeish IA
Nature Communications, Springer Nature vol. 14 (1) 
26-09-2023

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana I-G, Reinius MAV, Giannone G, Lewsley L-A, Stobo J, McQueen J, Bryson G, Eldridge M, Macintyre G, Markowetz F, Brenton JD and McNeish IA
Nature Communications, Springer Nature vol. 14 (1) 
20-07-2023

Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis
Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Burger Ramos M, Peerani E, Hirani P, Gauthier V, Liu Y, Maniscalco G, Rajeeve V, Cutillas P, Trevisan C, Pozzobon M, Lockley M, Rastrick J, Läubli H, White A and Pearce OMT
Nature Communications, Springer Nature vol. 14 (1) 
15-05-2023

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2
Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A and Rosenthal AN
Journal of Medical Genetics, Bmj vol. 60 (5), 440-449.  
01-11-2022

Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium
Fonseca A, Lobo J, Hazard FK, Gell J, Nicholls PK, Weiss RS, Klosterkemper L, Volchenboum SL, Nicholson JC, Frazier AL, Amatruda JF, Bagrodia A, Lockley M and Murray MJ
British Journal of Cancer, Springer Nature vol. 127 (9), 1577-1583.  
13-10-2022

600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials
Palmer KR, El-Shakankery KH, Kefas J, Gao K, Crusz S, Flynn M, Jonathan L, Lockley M, McCormack M, Macdonald N, Nicum S, Devlin M-J and Miller R
Annals of Oncology, Elsevier vol. 33 
01-09-2022

Letter to Editor in Response to: Controlled Aspiration of Large Paediatric Ovarian Cystic Tumors
Graham R, Stoneham S, Lockley M and MacDonald ND
Journal of Pediatric Surgery, Elsevier vol. 58 (10) 
12-08-2022

A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer
Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H, McNeish IA, Huang W, Maniati E, Graham TA and Lockley M
Gynecologic Oncology, Elsevier vol. 167 (1), 96-106.  
30-07-2022

Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L and Hirsch MS
European Journal of Cancer, Elsevier vol. 173, 59-70.  
18-07-2022

Abstract PR015: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer
Hockings H, Lockley M, Graham T, Lakatos E and Huang W
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (10_Supplement), pr015-pr015.  
15-05-2022

Abstract B001: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer
Hockings H, Lockley M, Graham T, Lakatos E and Huang W
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (10_Supplement), b001-b001.  
15-05-2022

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous CarcinomaGenomics of Early-Stage Ovarian High-Grade Serous Carcinoma
Cheng Z, Mirza H, Ennis DP, Smith P, Gavarró LM, Sokota C, Giannone G, Goranova T, Bradley T, Piskorz A, Lockley M, Investigators FTB, Kaur B, Singh N, Tookman LA, Krell J, McDermott J, Macintyre G, Markowetz F, Brenton JD and McNeish IA
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 28 (13), of1-of12.  
10-04-2022

Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study
Graham R, MacDonald ND, Lockley M, Miller R, Butler J, Murali K, Sarker S-J, Banerjee S, Stoneham S, Shamash J, Liberale V, Berney DM and Newton C
European Journal of Obstetrics & Gynecology and Reproductive Biology, Elsevier vol. 271, 138-144.  
16-02-2022

Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy
Hoare JI, Osmani B, O’Sullivan EA, Browne A, Campbell N, Metcalf S, Nicolini F, Saxena J, Martin SA and Lockley M
Communications Biology, Springer Nature vol. 5 (1) 
03-02-2022

423 Results of the avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance program for BRCA mutation-carriers
Philpott S, Raikou M, Manchanda R, Evans G, Edmondson R, Menon U, Ahmed M, Woodward E, Lamnisos A, Lockley M, Scott M, Singh N, Skates S, Mcguire A and Rosenthal A
International Journal of Gynecological Cancer, Bmj vol. 31, a373-a374.  
01-10-2021

Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study
Oxley SG, Achampong YA, Sambandan N, Hughes DJ, Thomas M, Lockley M and Olaitan A
Acta Obstetricia Et Gynecologica Scandinavica, Wiley vol. 100 (11), 2091-2096.  
05-09-2021

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study
Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, Khouly FE, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R and Lockley M
Cancers, Mdpi vol. 13 (17) 
27-08-2021

LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Lakatos E, Hockings H, Mossner M, Huang W, Lockley M and Graham TA
Iscience, Elsevier vol. 24 (8) 
21-07-2021

Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’
Lockley M, Stoneham S, Shamash J, Pashankar F and Frazier L
European Journal of Cancer, Elsevier vol. 152, 255-256.  
04-06-2021

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA and Lockley M
Cell Death & Disease, Springer Nature vol. 12 (4) 
14-04-2021

Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim H-S, Lee J-Y, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Network THCC and Singh N
Gynecologic Oncology, Elsevier vol. 161 (1), 328-329.  
05-02-2021

LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Lakatos E, Hockings H, Mossner M, Huang W, Lockley M and Graham TA
, Cold Spring Harbor Laboratory 
06-01-2021

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim J-W, Sundar S, Jayson GC, Ledermann JA and Clamp AR
The Lancet Oncology, Elsevier vol. 22 (2), 277-288.  
22-12-2020

Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients
Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, Agarwal S, Sahdev A, Wilson P, Harland S, Stoneham S, Lockley M, Rustin G, Oliver T, Berney D and Shamash J
European Journal of Cancer, Elsevier vol. 164, 105-113.  
08-10-2020

The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)
Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A, Barrett T, Alexander S, Rudman S, Lockley M, Berney D and Sahdev A
British Journal of Cancer, Springer Nature vol. 124 (2), 368-374.  
29-09-2020

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer
Hoare JI, Hockings H, Saxena J, Silva VL, Maniati E, Mirza HB, Huang W, Wood GE, Nicolini F, Graham TA, McNeish IA and Lockley M
, Cold Spring Harbor Laboratory 
24-07-2020

Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Berney DM, Shamash J, Stoneham S and Lockley M
European Journal of Cancer, Elsevier vol. 130, 267-268.  
18-03-2020

Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448]
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim H-S, Lee J-Y, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Network THCC and Singh N
Gynecologic Oncology, Elsevier vol. 157 (2), 558-559.  
20-02-2020

Ovarian germ cell tumour classification: views from the testis
Berney DM, Stoneham S, Arora R, Shamash J and Lockley M
Histopathology, Wiley vol. 76 (1), 25-36.  
17-12-2019

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process
McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L and Lanceley A
International Journal of Gynecological Cancer, Bmj vol. 30 (2), 221-226.  
19-11-2019

Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA
Macintyre G, Goranova TE, Silva DD, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G and Nourse C
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 25 (22_Supplement), ap09-ap09.  
15-11-2019

The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases
Heath O
 
24-10-2019

GCT-30 Surgical management of ovarian germ cell tumours
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J and Lockley M
European Urology Open Science, Elsevier vol. 18 (4) 
01-09-2019

GCT-84 The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)
Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A, Barrett T, Alexander S, Stoneham S, Rudman S, O’Brien T, Lockley M and Berney D
European Urology Open Science, Elsevier vol. 18 (4) 
01-09-2019

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, Aggarwal S and Bronger H
Gynecologic Oncology 
20-05-2019

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Ledermann J, Berney DM, Shamash J, Banerjee S, Stoneham S and Lockley M
European Journal of Cancer, Elsevier vol. 113, 19-27.  
04-04-2019

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD and McNeish IA
British Journal of Cancer, Springer Nature vol. 120 (8), 868-868.  
13-03-2019

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results
Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R, Gilks B and Singh N
International Journal of Gynecological Cancer, Bmj vol. 29 (2) 
25-01-2019

Ovarian cancer in adolescents and young adults
Lockley M, Stoneham SJ and Olson TA
Pediatric Blood & Cancer, Wiley vol. 66 (3) 
23-10-2018

Copy number signatures and mutational processes in ovarian carcinoma
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G and Nourse C
Nature Genetics, Springer Nature vol. 50 (9), 1262-1270.  
13-08-2018

Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.
Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R and Kristeleit RS
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 36 (15_suppl), 5581-5581.  
20-05-2018

Mainstreamed genetic testing for women with ovarian cancer: first-year experience
Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T and Side L
Journal of Medical Genetics, Bmj vol. 56 (3) 
13-03-2018

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo‐ovarian high‐grade serous carcinoma before and after neoadjuvant chemotherapy
Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB and Singh N
Histopathology, Wiley vol. 71 (5), 736-742.  
07-08-2017

A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R, Douglas N, Pou C, Hanif A, Campbell C, Multani PS, Tucker T, McNeish IA and Evans TRJ
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 35 (15_suppl), 2594-2594.  
20-05-2017

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD and McNeish IA
British Journal of Cancer, Springer Nature vol. 116 (10), 1294-1301.  
30-03-2017

Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer.
La Russa M, Kokka F, Lockley M and Brockbank E
J Obstet Gynaecol, Taylor & Francis vol. 37 (2), 268-270.  
06-12-2016

CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden KH, Lockley M and McNeish IA
Cancer Research, American Association For Cancer Research 
16-08-2016

A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, Topping J, Cutillas PR, Lockley M, Serody JS, Capasso M and Balkwill FR
Clinical Cancer Research, American Association For Cancer Research 
27-06-2016

Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma
BALKWILL F, Anne Montfort and Oliver Pearce
Clinical Cancer Research, American Association For Cancer Research 
01-04-2016

Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer.
Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Lockley M and McNeish IA
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 22 (2_Supplement), b53-b53.  
15-01-2016

RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer
Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M, Martin SA and McNeish IA
Molecular Cancer Research, American Association For Cancer Research (Aacr) vol. 14 (1), 44-55.  
01-01-2016

Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity
Browne A, Tookman LA, Ingemarsdotter CK, Bouwman RD, Pirlo K, Wang Y, McNeish IA and Lockley M
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (14), 2811-2821.  
14-07-2015

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB and Singh N
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 33 (22), 2457-2463.  
29-06-2015

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M and McNeish IA
Molecular Oncology, Wiley vol. 9 (4), 791-805.  
29-12-2014

Adaptive immunity in cancer immunology and therapeutics.
Spurrell EL and Lockley M
Ecancermedicalscience vol. 8 
01-01-2014

Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.
Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T, Imhof BA, Balkwill FR and Nourshargh S
Faseb J vol. 27 (10), 4244-4253.  
01-10-2013

Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.
Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ, Willis AE, Lockley M and McNeish IA
Mol Ther vol. 20 (9), 1676-1688.  
01-09-2012

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S and Balkwill FR
J Pathol vol. 227 (2), 136-145.  
01-06-2012

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials
Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA and Carroll NR
Pancreatology vol. 12 (1), 8-15.  
01-01-2012

Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP and McNeish IA
J Clin Invest vol. 121 (4), 1283-1297.  
01-04-2011

Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.
Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR and McNeish IA
Mol Ther vol. 19 (3), 490-499.  
01-03-2011

Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer
Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP and McNeish IA
Human Gene Therapy vol. 22 (10), A113-A113.  
01-01-2011

p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.
Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR and McNeish IA
Mol Cancer vol. 9 
03-07-2010

Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer
Lolkema M, Lockley M, Zhou H, Duffner J, Kishomoto TK and Tuveson DA
Cancer Research, American Association For Cancer Research (Aacr) vol. 70 (8_Supplement) 
15-04-2010

Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer
Lockley M and Eisen T
Journal of Clinical Practice, Omics International vol. 6 (1), 111-124.  
01-01-2009

Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.
Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR and McNeish IA
Oncogene vol. 27 (22), 3081-3090.  
15-05-2008

Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging.
Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR and McNeish IA
Cancer Res vol. 66 (18), 9178-9185.  
15-09-2006

Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.
Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N and McNeish I
Cancer Res vol. 66 (2), 989-998.  
15-01-2006

Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis.
McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP and Lemoine NR
Exp Cell Res vol. 302 (1), 69-82.  
01-01-2005